Skip to Content

CNBX Pharmaceuticals Inc CNBX

Morningstar Rating
$0.01 0.00 (24.17%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CNBX is trading at a 46% discount.
Price
$0.01
Fair Value
$6.76
Uncertainty
Extreme
1-Star Price
$3.16
5-Star Price
$3.67
Economic Moat
Wqxv
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CNBX is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.01
Day Range
$0.010.01
52-Week Range
$0.010.05
Bid/Ask
$0.01 / $0.01
Market Cap
$463,559.14
Volume/Avg
61,463 / 199,067

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.20
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
2

Valuation

Metric
CNBX
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
0.20
Price/Cash Flow
Price/Earnings
CNBX

Financial Strength

Metric
CNBX
Quick Ratio
0.06
Current Ratio
0.06
Interest Coverage
Quick Ratio
CNBX

Profitability

Metric
CNBX
Return on Assets (Normalized)
−647.17%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
CNBX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWjfdsxnjrTnxlm$558.5 Bil
REGN
Regeneron Pharmaceuticals IncGzhyvltNthdff$102.8 Bil
VRTX
Vertex Pharmaceuticals IncTzvcmcfMmvrjn$102.5 Bil
MRNA
Moderna IncXrxpkgpsDbnm$41.0 Bil
ARGX
argenx SE ADRFqmxhvbKkc$22.8 Bil
BNTX
BioNTech SE ADRZwzphpdgMgldf$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncFhtdgxzDvtpnb$18.8 Bil
BMRN
Biomarin Pharmaceutical IncRmjzrtjtfVwjtgy$17.4 Bil
RPRX
Royalty Pharma PLC Class AJwbthhxyFvbthb$12.6 Bil
INCY
Incyte CorpHwjggrmFxkkdq$12.4 Bil

Sponsor Center